It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Butembo, a bustling city of almost a million people in the eastern Democratic Republic of Congo, is reporting an increasing number of cases of Ebola virus disease in the country's current epidemic.
Butembo is a key trading and transport hub with links to other major cities in the country as well as to neighboring Uganda. It's about two times the size of the city of Beni, the outbreak's epicenter, and is located just 35 miles away. The health ministry said the "high density and mobility" of Butembo's population presents new challenges to containment efforts, already complicated by sporadic rebel attacks on remote villages in and around Beni.
some limited and appropriate deviation from standard research expectations in disaster situations is increasingly accepted.
New guidelines are needed that better define the boundaries between using medicines for compassionate use and conducting a clinical trial.
5. Is participation in the ring vaccination voluntary?
Yes. Participation in this “expanded access” or “compassionate use” of the Ebola vaccine is entirely free and voluntary. Each eligible person makes their own decision whether to participate or not and can withdraw at any time. Their rights will be respected. Disregard of whether the eligible person chooses to participate or not, it will not have an impact on their access to health services.
Tell someone they have Ebola then tell them you have a new drug you want to try and ask them if its ok.
4. How is the ring vaccination done?
A ring vaccination tracks the epidemic, recruiting individuals at raised risk of infection due to their connection to a patient confirmed with the virus.
6. Who are eligible for the vaccine?
Each person to be considered for the expanded access of the vaccine will receive one dose of the vaccine. The persons to be considered include:
Contacts, and contacts of contacts of confirmed Ebola virus disease patients (dead or alive),
Health care and frontline workers (local and international) in the affected areas, and
Health care and frontline workers in areas at risk of spread of the outbreak
WHO convened a meeting of scientific experts to evaluate the available information and data on investigational therapeutics intended to treat Ebola virus disease (EVD). The purpose of the meeting was to consider whether the available information supported MEURI for access to investigational therapeutics on an individual patient basis for treatment of EVD during the current outbreak, outside of clinical trial.